Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product
The companies that had originally nominated the peptides for restriction withdrew their nominations, and on April 15, 2026 the FDA published the action, with the peptides coming off the Category 2 list effective April 22 to 23, 2026
We offer injections in multiple forms because not everyone metabolizes B12 the same way, and the form actually matters more than most patients realize
Cyanocobalamin is indicated for Vitamin B12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacterial overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue
Investigated in performanceoriented models for its role in cellular energy and metabolism pathways
